Pfizer in November released initial trial results on the vaccine that is currently under review by health regulators in both the United States Europe. The U.S. Food and Drug Administration is expected to decide on its use by August.
New Delhi: Pfizer Inc’s experimental respiratory syncytial virus (RSV) vaccine was 82 per cent effective in preventing severe infections in infants when given to expecting mothers in the second half of their pregnancy, according to trial details published on Wednesday that confirm preliminary data from the study.
Comments are closed.